Biomarker | SemiQ/Q | Disease | Question answered | Utility of biomarker | Data from | Potential decision for | |
---|---|---|---|---|---|---|---|
Non-malignant disease | Volumetric high resolution CT density (quantitative interstitial lung disease, QILD) | Q | Scleroderma | Response to cyclophosphamide | 24-month changes in QILD scores in the whole lung correlated significantly 24-month changes in forced vital capacity (ρ = − 0.37), diffusing capacity (ρ = − 0.22) and breathlessness (ρ = − 0.26) [164] | Single centre | Continue, change or stop treatment |
Left Ventricular ejection fraction LVEF | Q | Pulmonary hypertension Myocardial ischaemia/infarction | Right and left cardiac sufficiency Improvement in cardiac function | Increases in 6-min walk distance were significant correlated with change in right ventricular ejection fraction and left ventricular end-diastolic volume [165] Monitoring cardiac function [166] | Multicentre Multicentre | Continue, change or stop treatment | |
Malignant disease | RECIST/morphological volume | Q | Cancer | Response | Current guidelines for response assessment [167] | Multicentre | Continue, change or stop treatment |
PERCIST/metabolic volume [168] | Q | Cancer | Response | Current guidelines for response assessment | Multicentre | Continue, change or stop treatment | |
Scoring systems for disease burden | SQ | Multiple sclerosis Rheumatoid arthritis | Reduction in disease burden | Effects on MRI lesions over 6–9 months predict the effects on relapses at 12–24 months) [169] International consensus on scoring system [170] | Meta-analysis Review | Continue, change or stop therapy | |
DSC-MRI | SQ (rCBV) | Brain cancer | Differentiation of treatment effects and tumour progression | In 2 meta-analyses MRI had high pooled sensitivities and specificities: 87% (95% CI, 0.82–0.91) to 90% (95% CI, 0.85-0.94) sensitivity and 86% (95% CI, 0.77–0.91) to 88% (95% CI, 0.83-0.92) specificity [171, 172] | Meta-analysis | Decision to treat | |
18F FDG-SUVmax [173] | Q | Multiple cancer types | Response to therapy | Rectal cancer-pooled sensitivity, 73%; pooled specificity, 77%; pooled AUC, 0.83 [174] Intratreatment low SUVmax (persistent low or decrease of 18F-FDG uptake) predictive of loco-regional control in head and neck cancer [175] | Meta-analysis Meta-analysis | Continue, change or stop therapy | |
Deauville or RECIL score on 18 F-FDG-PET | SQ | Lymphoma | CR, PR, SD or PD [176] | Assessment of tumour burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions [177] | Multicentre | Continue, change or stop therapy | |
Targeted agents HER2 PSMA | SQ | Breast cancer [178] Prostate cancer [179] | Reduction in tumour cells expressing these antigens | Tumour receptor specific Effects of treatment on receptor expression | Single centre studies, review | Continue, change or stop therapy | |
ADC [117] | SQ Q | Rectal cancer Breast cancer | Response to neoadjuvant chemotherapy Response to neoadjuvant chemotherapy | Additional value in both the prediction and detection of (complete) response to therapy compared with conventional sequences alone [180] After 12 weeks of therapy, change in ADC predicts complete pathologic response to neoadjuvant chemotherapy (AUC = 0.61, p = 0.013) [181] | Review Multicentre | Continue, change or stop therapy, proceed to surgery | |
CT perfusion/blood flow | Q | Oesophageal cancer | Response to chemoradiotherapy | Multivariate analysis identified blood flow as a significant independent predictor of response [182] | Single centre | Further treatment | |
DCE-MR parameters | Q | Multiple cancer types | Response to therapy | Particular benefit in assessing therapy response to antiangiogenic agents [183] | Review | Change therapeutic strategy | |
CT density HU | Q | Gastrointestinal stromal tumours | Response to chemotherapy | Decrease in tumour density of > 15% on CT had a sensitivity of 97% and a specificity of 100% in identifying PET responders versus 52% and 100% by RECIST [184] | Continue, change or stop therapy |